Rant… [Off Topic]
To whom it may concern!
Not only in the forum but in my daily work as a consultant I’m increasingly often confronted with “creative” study designs where the underlying statistical methodology is either dubious or currently nonexistent at all. Just to name a few:limited no knowledge about existing methods, their underlying assumptions/limitations and/or purposes. “Classical” examples are blindly following FDA’s partial replicate design or believing that the 94.12% confidence interval is applicable to all two-stage designs (aka Pocock’ natural constant α 0.0294). When asked a common answer is “We planned to evaluate the study with SAS…”. Bingo! It also often unfolds that their main sources of information are guidelines, presentations found on the internet, or forum posts / blogs.
Only a minority might have read original publications beyond their abstracts.
Amazingly these (Internet-Generation?) attitudes are not limited to people working in the industry but to regulators as well. Recently I received a question from an ASEAN-assessor which boiled down to:
—
SCNR,
Helmut (the grumpy old man)![[image]](img/CC80x15.png)
Profile «accessible to registered users only»
The quality of responses received is directly proportional to the quality of the question asked. ☼
→ Science Quotes
Not only in the forum but in my daily work as a consultant I’m increasingly often confronted with “creative” study designs where the underlying statistical methodology is either dubious or currently nonexistent at all. Just to name a few:
- “Two-stage replicate designs” intended for reference-scaling. Method? Patient’s risk?
- Replicate designs with more than two treatments. Method?
- Futility rules in two-stage designs. Power?
- Two-stage designs for parallel groups. Heteroscedasticity? Patient’s risk? Power?
- Planning a pivotal study based on a single published CV…
Only a minority might have read original publications beyond their abstracts.
To call the statistician after the experiment is done
may be no more than asking him to perform a postmortem examination:
he may be able to say what the experiment died of. RA Fisher
Amazingly these (Internet-Generation?) attitudes are not limited to people working in the industry but to regulators as well. Recently I received a question from an ASEAN-assessor which boiled down to:
“A generic product has demonstrated bioequivalence in a well-powered in vivo study. However, the formulation failed to show f2 ≥50 in all pH-values tested. Can I still accept the application?”
—
SCNR,Helmut (the grumpy old man)
![[image]](img/CC80x15.png)
Profile «accessible to registered users only»
The quality of responses received is directly proportional to the quality of the question asked. ☼
→ Science Quotes
